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Copy-number variation (CNV) is a major contributor to human genetic variation. Recently, CNV associations with human disease have
been reported. Many genome-wide association (GWA) studies in complex diseases have been performed with sets of biallelic single-
nucleotide polymorphisms (SNPs), but the available CNV methods are still limited. We present a new method (TriTyper) that can infer
genotypes in case-control data sets for deletion CNVs, or SNPs with an extra, untyped allele at a high-resolution single SNP level. By
accounting for linkage disequilibrium (LD), as well as intensity data, calling accuracy is improved. Analysis of 3102 unrelated individuals
with European descent, genotyped with Illumina Inﬁnium BeadChips, resulted in the identiﬁcation of 1880 SNPs with a common
untyped allele, and these SNPs are in strong LD with neighboring biallelic SNPs. Simulations indicate our method has superior power
to detect associations compared to biallelic SNPs that are in LD with these SNPs, yet without increasing type I errors, as shown in
a GWA analysis in celiac disease. Genotypes for 1204 triallelic SNPs could be fully imputed, with only biallelic-genotype calls, permitting
association analysis of these SNPs in many published data sets. We estimate that 682 of the 1655 unique loci reﬂect deletions; this is on
average 99 deletions per individual, four times greater than those detected by other methods. Whereas the identiﬁed loci are strongly
enriched for known deletions, 61% have not been reported before. Genes overlapping with these loci more often have paralogs
(p ¼ 0.006) and biologically interact with fewer genes than expected (p ¼ 0.004).Introduction
It has become apparent that copy-number variation (CNV)
accounts for a considerable amount of genetic variation1–5
and has been implicated as a causal mechanism for several
disorders.6–8 Specialized comparative genomic hybridiza-
tion (CGH) arrays that contain large-insert clones that hy-
bridize to complementary DNA1,5,9,10 have providedmuch
insight into the properties of CNVs. These studies have
shown that individuals usually carry many small-deletion
and duplication CNVs that can be found with high popu-
lation frequencies.
Recently, much effort has been devoted to detecting
CNVs with single-nucleotide polymorphism (SNP) geno-
type data in both familial and unrelated samples.2,4,11–19
An important resource so far has been the HapMap pro-
ject,20 in which over three million SNPs have been typed
for 270 samples. In addition, growing resources of geno-
type data from oligonucleotide arrays that usually assay
at least 300,000 SNPs have been generated for genome-
wide association (GWA) studies. Although there are techni-
cal challenges to detecting CNVs with these arrays,21 vari-
ous methods have been developed. Some have been
designed to work on single samples,13,14,17–19,22 using sim-
ilar principles as used for array CGH, whereas others take1316 The American Journal of Human Genetics 82, 1316–1333, Junemultiple samples jointly into consideration.2,4,15,22 The
single-sample methods typically require that multiple,
consecutive (usually at least three) SNPs show deviations
in the allele intensity signals. When multiple samples are
analyzed together, genotype calls, based on biallelic SNP
assumptions, can provide circumstantial evidence that
CNVs span these SNPs. SNPs that map within common
CNVs are expected to show deviations from Hardy-Wein-
berg equilibrium (HWE) and an increased number of miss-
ing genotype calls. If family data are present, a control for
Mendelian segregation is routinely performed. Usually this
is done to determine genotyping accuracy, but if for a given
SNP segregation inconsistencies are observed, these can
also be caused by violations of the assumption that the
SNP is biallelic: Duplications, deletions, or the presence
of a third allele at the locus that is not labeled by the assay
can all lead to observations of Mendelian inconsistency.
One limitation of the available CNV detection methods
is the resolution because nearly all require that multiple
consecutive SNPs show aberrant intensity characteris-
tics.4,13,14,16–19,22 One method has a resolution as high as
a single SNP,15 but it can only be applied to families.
Here, we describe a new genotype-calling method (‘‘Tri-
Typer’’) that can reliably detect deletions in unrelated sam-
ples that span only one SNP. Our algorithm detects SNPs1Complex Genetics Section, DBG-Department ofMedical Genetics, UniversityMedical Centre Utrecht, 3584 CGUtrecht, The Netherlands; 2Department of
Epidemiology & Biostatistics, Erasmus MC Rotterdam, 3000 CA Rotterdam, The Netherlands; 3Genetics Department, University Medical Centre Groningen
and University of Groningen, 9700 RB Groningen, The Netherlands; 4Institute of Cell and Molecular Science, Barts and The London School of Medicine
and Dentistry, London, E1 2AT, UK; 5Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, 3584 CX
Utrecht, The Netherlands; 6Center for Neurobehavioral Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095,
USA; 7Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
*Correspondence: c.wijmenga@umcutrecht.nl
DOI 10.1016/j.ajhg.2008.05.008. ª2008 by The American Society of Human Genetics. All rights reserved.2008
with an extra, untyped allele (including deletion CNVs
encompassing these SNPs) with raw intensity data from
Illumina Inﬁnium HumapHap300 and HumanHap550
BeadChip arrays.23 Using TriTyper, we identiﬁed 1880
SNPs with a common extra allele (frequency >0.5%) in a
collection of 3102 DNA samples from individuals of North-
west European origin. Our method can accurately assign
genotypes by utilizing local linkage disequilibrium (LD)
with nearby SNPs.1,24,25 We show that our procedure re-
sults in correct genotype assignments through aMendelian
segregation analysis in white European HapMap trios, in
which many segregation inconsistencies, observed under
biallelic-calling assumptions, are resolved when triallelic
genotypes have been assigned. Of the 1880 triallelic
SNPs, 1204 can be fully imputed from surrounding SNPs
without the need to use raw intensity data. This is helpful
when analyzing triallelic SNPs in publicly available and
other data sets for which only genotype calls have been
made available. We show how these triallelic genotypes
can be used for association studies and that our test statistic
shows no inﬂation in signiﬁcant signals as exempliﬁed in
an analysis of celiac disease (MIM 212750). Yet, like other
imputation methods,26,27 our method has superior power
to detect true positive associations, when contrasted to
an association analysis of nearby biallelic SNPs, used for
imputing the triallelic SNPs. The identiﬁed triallelic loci
are strongly enriched for known deletions, but the major-
ity of identiﬁed deletions have not yet been described.
We support previous ﬁndings that genes, mapping within
these deletions, more often have paralogs, but we also
found that the genes usually tend to interact biologically
with fewer genes than expected. With TriTyper, more ge-
netic information can be captured, triallelic SNP genotypes
can be imputed, and interesting phenomena, including
small-deletion CNVs, can be detected in numerous case-




Oligonucleotide assays, available for high-throughput SNP geno-
typing, usually measure the intensities of two ﬂuorescent labels
that are attached to two known alleles, A and B. Throughout
this paper, these are plotted on the x axis (intensitya) and y axis
(intensityb), respectively. When an extra, untyped allele (a ‘‘null’’
or 0 allele) is present, up to six clusters (representing AA, AB, BB,
A0, B0, and 00 genotypes) in the raw intensity plot will become
visible (Figure 1A). Usually, these A0 and B0 clusters partly overlap
with the AA and BB clusters, respectively, whereas the 00 cluster
has a very low Euclidian intensity. We refer to this as a ‘‘triallelic’’
pattern or ‘‘triallelic’’ SNP. If the presence of this null allele is not
recognized, standard calling algorithms will typically call A0 and
B0 genotypes as AA and BB, respectively, and 00 genotypes as
‘‘failed.’’ Under biallelic assumptions, deviations from HWE are
then likely to become apparent.
We used these deviations under biallelic assumptions as the ba-
sis for our triallelic genotype-calling algorithm (TriTyper). TriTyperThe Amextends a biallelic genotype-calling algorithmwe have recently de-
veloped28 and models triallelic genotypes by using a maximum-
likelihood estimation (MLE) procedure that optimizes HWE under
triallelic assumptions29 (Figures 1A–1D; for details, see Appendix
A). Another key aspect of our method is that it uses the presence
of local LD between this null allele and nearby biallelic
SNPs1,24,25 to gain evidence that the extra allele has been correctly
identiﬁed. Once this has been established, it takes advantage of
these biallelic SNPs to improve the triallelic-genotype assignments
by using a fairly straightforward imputation method (Figures 1E–
1G; for details see Appendix A) that borrows some ideas from
methods that impute genotypes for biallelic SNPs.26,27 This impu-
tation methodology often allows for accurately discriminating
between A0 and AA and between B0 and BB samples; such discrim-
ination is particularly helpful because these clusters usually over-
lap somewhat (Figure 1G, green arrow).
Data Sets for Triallelic-SNP Discovery
Initial analyseswereperformedonacohort that comprised1422un-
related control individuals28 from the 1958Britishbirth cohort that
passed quality control (QC) and had been typed on the Illumina
Inﬁnium II Human Hap550 BeadChip platform for 571,738 SNPs.
To also detect triallelic SNPs with lower null-allele frequencies, we
added three more cohorts. These included 778 unrelated UK celiac
disease cases,28 450 unrelated Dutch controls,30 and 472 unrelated
Dutch amyotrophic lateral sclerosis (MIM 105400) cases30 that all
passed QC and had been typed on the Illumina Inﬁnium II Human
Hap300 BeadChip platform for 317,503 SNPs. In this combined
analysis, 313,505 SNPs could be analyzed because theywere present
on both the Hap300 and Hap550 platforms. A total of 20 samples
(0.6%) showed aberrant intensity signals for many of the triallelic
SNPs and were removed from the analyses.
Association Analysis
An analysis for marginal association effects on the biallelic SNPs
used for imputation of the triallelic SNPs was performed as follows:
Analyses were conﬁned to SNPs for which the null allele was not in
complete LD with a biallelic SNP because for these SNPs, Fisher’s
exact test for association would be identical to the association
analysis of the triallelic null allele. Only triallelic SNPs, in which
one biallelic SNP could help to discriminate between A0 and AA
genotypes and another biallelic SNP could help to discriminate
between B0 and BB genotypes, were included in the analysis.
To assess the marginal effect on the SNPs used for imputing the
triallelic SNPs, we simulated three different scenarios of triallelic
SNP association (Fisher’s exact test for the triallelic null allele of
104, 106, and 108). For each triallelic SNP, an equal number
of controls and cases were chosen, but case and control labels
were assigned in such a way that association for the triallelic
SNP yielded a Fisher’s exact p value for the null-allele that approx-
imated the p value of the scenario under investigation. This
allowed for determining the marginal association effect on the
two biallelic SNPs used for imputing each triallelic SNP. We
repeated this 100 times to gain accurate estimates. Subsequently,
for each triallelic SNP, the average marginal effect on the biallelic
SNP that was associated most signiﬁcantly was recorded. Once
this was performed for all the triallelic SNPs, the median marginal
effect could be determined for each scenario.
The triallelic SNP null-allele association analysis was performed
on a celiac disease GWA data set28 and was conﬁned to those trial-
lelic SNPs for which imputation could help to discriminateerican Journal of Human Genetics 82, 1316–1333, June 2008 1317
Figure 1. Genotyping Methodology for SNPs with a Third, Untyped Allele
The graphs show the intensities of the A labeled probe (x axis) and B labeled probe (y axis) of both a theoretical SNP with an third, un-
typed allele (top figures) and a real SNP (rs7571895, bottom figures). (A) shows that six genotypes for a triallelic SNP exist. The A0 and
AA, and B0 and BB, genotype clusters usually overlap somewhat. (B) shows that initially 00 genotypes are assigned to samples that have
an intensity lower than threshold a. The remaining samples are designated an initial A0/AA, AB, or B0/BB genotype with an existing
calling algorithm. As shown in (C), parameter b is then used to discriminate between A0 and AA and between B0 and BB genotypes
(see text). This allows for determining whether Hardy-Weinberg equilibrium is observed. As shown in (D), parameters a and b are
then optimized (with a maximum-likelihood-estimation procedure) until the SNP does adhere to Hardy-Weinberg equilibrium conditions.
Triallelic-genotype assignments, based on the MLE procedure for SNP rs7571895, are shown in (E). (F) shows that subsequent analysis of
neighboring SNPs results in the identification of biallelic SNP rs654797, which is in strong LD with the null allele of rs7571895. Although
LD does not seem to be perfect (r2< 1), we assume that this is probably because of imperfections in the initial genotype assignments and
that some of the haplotypes (indicated with an asterisk) are not actually present. This allows for identifying a set of triallelic genotype
imputation rules that are applied to the data and result in (G) improved genotype assignments for rs7571895, as is clearly visible when
distinguishing C0 from CC samples (green arrow) and 00 from A0 samples (black arrow).between both the A0 and AA samples and between the B0 and BB
samples. We did this because different arrays had been used to ge-
notype cases and controls. Although these arrays for most SNPs
show highly comparable intensity characteristics, for some SNPs,
subtle differences are present. When nearby biallelic SNPs can
only help to discriminate between A0 and AA or between B0
and BB, spurious associations are to be expected because of the
way our calling algorithm initially discriminates between A0 and
AA and between B0 and BB genotypes. Because of the normally
low frequency of the null allele, a Fisher’s exact test was performed
for testing the association signiﬁcance. Type I errors were ascer-
tained by a quantile-quantile (Q-Q) plot, generated by plotting
the observed ordered null-allele associations against the ordered
expected associations. Then we ﬁtted a line to the lower 90% of
the distribution, of which the slope (linﬂation) denotes either the
inﬂation or deﬂation of the test statistic.
Segregation Analysis
A segregation analysis was performed on 16 CEU trios for which
biallelic-genotype data had been generated on the Illumina Inﬁn-
ium II Human Hap650 platform (containing 660,918 SNPs). We1318 The American Journal of Human Genetics 82, 1316–1333, Junechose this data set because no genotypes formany of the identiﬁed
triallelic SNPs were available in the Phase II release from HapMap;
this was because of the fact that SNPs showing segregation incon-
sistencies in multiple trios were not included in this release.
Triallelic SNPs were included for analysis if genotypes could be
imputed on the basis of the biallelic calls; thus without directly
relying upon the raw intensity data, this method required that
genotype calls for these SNPs and the biallelic SNPs used for impu-
tation were available. Imputation allowed us to inspect visually
whether the raw-intensity-data patterns corresponded well to
the imputed genotype assignments. Subsequently, we used these
imputed triallelic genotypes to assess howmany of the Mendelian
segregation inconsistencies observed under biallelic assumptions
could be resolved. We took a conservative approach, because we
did not score segregation inconsistencies in the analysis of the
biallelic-genotype calls in trios in which a genotype had not
been called for either the mother or the father.
Identity of Untyped Alleles
Various sources can result in the detected null alleles within the
identiﬁed triallelic SNPs. Deletion CNVs that span these SNPs2008
will result in these triallelic intensity characteristics, whereas a pre-
viously unknown, third nucleotide at the physical position of the
SNP gives the same results. Alternatively, it is possible that within
the immediately adjacent locus that is complementary to the
50 bp primer of the SNP (used in the Illumina Inﬁnium chemis-
try), there is a secondary polymorphism that affects the hybridiza-
tion efﬁcacy of the primer and that will consequently result in the
same triallelic pattern.31
Todiscriminatebetween these threepossible explanations,we in-
vestigated whether there was any evidence that these SNPs reside
within deletion CNVs. If a deletion CNV is large enough to span
multiple assayed SNPs, these SNPs should all show a triallelic inten-
sity characteristic. It is likely theywill all be identiﬁed by our calling
method, but somemight bemissed (type II error). Toovercome this,
for each triallelic SNP we assessed whether its neighboring SNPs
showed characteristics suggesting the presence of a triallelic pat-
tern. It is expected that if this is the case, a neighboring SNP (such
as the triallelic SNP) will show Euclidian intensities for the triallelic
A0 and B0 samples that are signiﬁcantly lower than the intensities
of the samples with a triallelic AA, AB, or BB genotype.
We ﬁrst corrected for differences in probe intensity characteris-
tics within these neighboring SNPs through ranking the Euclidian
intensities of the samples that had an AA genotype for the neigh-
boring SNP and through ranking the Euclidian intensities of the
samples that had a BB genotype for the neighboring SNP. We
linearly scaled these two rankings to [0, 1] and assigned a value
of 0.5 to samples that were heterozygous for the neighboring
SNP. We then compared the ranked intensities of the samples
that had been assigned triallelic 00, A0, or B0 genotypes with
the ranked intensities of samples with triallelic AA or BB genotypes
and required that ranked intensities of the 00, A0, and B0 samples
were signiﬁcantly lower (one-sided Wilcoxon-Mann-Whitney test
p value < 105). We then called genotypes under biallelic assump-
tions for the neighboring SNP.We also required that loss of hetero-
zygosity (LOH) was observed (Fisher’s exact test p value < 0.01) in
the samples that had been assigned 00, A0, or B0 genotypes for the
triallelic SNP. However, we only tested for this if the minor allele
frequency of the neighboring SNP was high enough, such that
in a theoretical situation in which no AB samples were present,
the LOH Fisher’s exact test p value would be below 0.001.
We ﬁrst performed this analysis for the immediately adjacent
SNPs and then moved farther to the left and right, continuing as
long as the above conditions applied. Because the A0 and AA clus-
ters and B0 and BB clusters usually overlap somewhat, we reasoned
that if a deletion spans several SNPs, a better separation between
A0 and AA samples and between B0 and BB samples would be ob-
tained if we averaged the ranked intensities of these SNPs per sam-
ple. We applied this as an extra criterion for determining how far
a deletion is likely to extend. Apart from the above criteria, we also
required that, when we included more neighboring SNPs to the
left and right of the triallelic SNP, the averaged ranked intensity
differences between the samples with an A0 or B0 genotype and
the samples with an AA and BB genotype should consistently
become more signiﬁcant.
Thesecriteriameantwecoulddetermine the locus size for eachﬁt-
ted triallelic SNP. Immediately overlapping and adjacent loci were
concatenated, resulting in loci that ranged in size between one
SNP and loci that contained multiple ﬁtted SNPs and/or neighbor-
ing SNPs that showed aberrant intensity characteristics and LOH.
To identify SNPs for which the observed triallelic intensity char-
acteristic was due to a polymorphism in the primer region, we de-
rived the physical genomic positions in which the 50 bp primersThe Amannealed and determined whether more polymorphisms had
been described within these loci in dbSNP (build 127). All analyses
were performed on the NCBI build 36 genome assembly.
All the triallelic loci identiﬁed were categorized into loci that
contained multiple consecutive triallelic SNPs, loci that contained
one SNP for which no polymorphisms within the primer were
known, and loci that contained one single triallelic SNP and for
which a primer polymorphism was known.
Resequencing
We selected 23 triallelic SNPs for resequencing. Two were selected
to corroborate our prediction that the null allele for these was
caused by primer polymorphisms.We selected an additional 21 tri-
allelic SNPs to get an estimate of what proportion of the identiﬁed
null alleles reﬂects primer polymorphisms and what proportion
reﬂects deletions. To assess the quality of the genotype predic-
tions, we selected triallelic SNPs with different inferred genotype
qualities. We selected samples for all six genotypes when possible.
Primers were designed such that we PCR ampliﬁed ~500 base pairs
around the triallelic SNPs. On average, nine samples were
sequenced per SNP. Sequencing was performed according to stan-
dard protocols on an ABI 3730 (Applied Biosystems) sequencer.
Genomic Properties of Triallelic Loci
Ensembl32 version 41.36c was used for annotation purposes and
mapping of gene identiﬁers to Ensembl gene names. The size of
each identiﬁed locuswasdeﬁnedby taking thephysical distancebe-
tween the two immediate biallelic SNPs that enclosed it. The signif-
icance of underrepresentations or overrepresentations for each of
the various genomic properties was empirically determined by per-
muting all loci across the genome 1000 times, through deﬁning the
loci randomly around SNPs that were present on the Illumina
Hap550 chip, and ensuring that the size of these permuted loci
was equal to the real distribution. Known deletion CNVs were de-
rived from theDatabase of GenomicVariants3 (March 2007 release,
NCBI build 36 mapping). We assessed enrichment of the loci for
these deletions by determining how many loci overlapped with
known deletion CNVs and by ﬁtting an extreme value distribution
(EVD) on the permuted loci with the EVD add-on package33 to R (R
Development Core Team 2003, version 2.4.1). The Online Mende-
lian Inheritance in Man34 morbid map (downloaded on 6 Decem-
ber 2006) was used for the enrichment analysis of disease genes
that overlapped with our loci. Enrichment analysis of genes with
known paralogs was determined empirically by dreviation of all
knownparalogs fromEnsembl andassessmentofwhether thenum-
berof genes thatoverlappedwith the identiﬁed lociwith knownpa-
ralogs was higher than within the permutations. Known biological
interactions were derived from KEGG,35 BioGrid,36 Reactome,37
BIND,38 HPRD,39 and IntAct40 (all downloaded on 17 April 2007).
Interaction-depletion analysis for the genes, overlapping with the
identiﬁed loci,wasdeterminedbycontrasting thedistributionof the
number of interactions (‘‘degree’’) for each of these genes against
the distribution of the degree of the genes that were present within
the 1000 permutations, with a Wilcoxon-Mann-Whitney test.
Results
Identiﬁcation of 1880 Triallelic SNPs
TriTyper initially determines which SNPs show deviation
from HWE under biallelic assumptions, which provideserican Journal of Human Genetics 82, 1316–1333, June 2008 1319
evidence that an extra, untyped allele might be present for
these SNPs (see Figure 1A and details in Appendix A). For
these SNPs, we tried to ﬁt ‘‘triallelic’’ genotypes (Figure 1A,
see details in Appendix A). Initially, we used parameter a to
identify a putative set of samples with 00 genotypes and
assigned preliminary A0/AA, AB, and B0/BB genotypes to
the remaining samples (Figure 1B). We used parameter
b to distinguish both between A0 and AA samples and
between B0 and BB samples (Figure 1C). By adjusting
a and b, and using a maximum-likelihood estimation pro-
cedure, we could then ﬁnd a triallelic-genotype assignment
in which HWE was observed (Figure 1D). We then looked
for circumstantial evidence that this untyped allele had
been correctly identiﬁed (Figure 1E) by searching nearby
biallelic SNPs that are in near perfect LD with this null
allele (Figure 1F). Because some of the initially assigned
genotypes might be incorrect, we can use this LD to im-
prove upon the triallelic genotyping through imputation
(Figure 1G, green and black arrows) (see details in
Appendix A).
By applying this algorithm to 1,417 unrelated UK con-
trols, genotyped for 571,738 SNPs (Illumina Human
Hap550 array), we identiﬁed 1,535 triallelic SNPs (median
null-allele frequency ¼ 8.6%). To be able to detect triallelic
SNPs with a lower null-allele frequency, we increased the
sample size to 3102, by adding 768 unrelated UK celiac
patients, 445 unrelated Dutch controls, and 472 unrelated
Dutch amyotrophic lateral sclerosis patients. Because these
samples had been typed on the Illumina Human Hap300
array, this analysis was restricted to the 313,505 SNPs that
were present on both array types. We identiﬁed 958 trial-
lelic SNPs, of which 345 (median null-allele frequency ¼
4.7%) had not been identiﬁed in the smaller cohort. Clus-
ter plots of all 1880 triallelic SNPs are available on the
TriTyper website.
The presence of LD between these null alleles and nearby
biallelic SNPs provides strong evidence that an untyped
allele has been correctly identiﬁed for these triallelic
SNPs. In addition, once the presence of this LD had been
established, we utilized it to partly impute the triallelic ge-
notypes. For 1204 (64%) of the 1880 triallelic SNPs, impu-
tation is capable of discriminating both between A0 and AA
and between B0 and BB samples. In these cases, biallelic-ge-
notype calls sufﬁce to infer these ‘‘fully imputable’’ triallelic
genotypes. This allows for performing association analysis
of triallelic SNPs in GWA studies for which only biallelic-
genotype calls have been made publicly available41,42 or
when different genotyping assays have been used.
To assess how well imputation functions when only
biallelic-genotype calls and no raw intensity data were
available, we performed a Mendelian segregation analysis
on genotype data from 16 CEU trios. For these samples,
biallelic-genotype calls were available for 1153 (96%) of
the 1204 fully imputable triallelic SNPs (see Material and
Methods). A total of 431 (37%) SNPs showed segregation
inconsistencies under biallelic assumptions. When imput-
ing triallelic genotypes, this decreased to 319 (28%). This1320 The American Journal of Human Genetics 82, 1316–1333, Juneindicates that some segregation inconsistencies can indeed
be resolved. We reasoned that if the LD was high between
the null allele and the biallelic SNPs used for imputation,
the genotypes should mostly be correct and would resolve
most of the observed segregation inconsistencies. To assess
this, we conﬁned the analysis to those triallelic SNPs in our
cohort for which the observed concordance between the
preliminary triallelic genotypes determined and the subse-
quently imputed triallelic genotypes was at least 90%. Of
these 596 triallelic SNPs, 257 (43%) showed Mendelian
segregation inconsistencies when they were called under
biallelic assumptions, compared to 60 (10%) when the im-
puted triallelic genotypes (individual segregation plots are
available at the TriTyper website) were used. This implies
that for the great majority of the identiﬁed SNPs, an extra
allele has indeed been typed but that most of these trial-
lelic genotypes can be correctly imputed when the LD is
sufﬁciently high. Additionally, the concordance between
the preliminary assigned triallelic genotype and eventually
imputed genotypes serves as a quality statistic measure of
the triallelic-genotype calling.
Association Analysis
Because most GWA studies aim to identify new susceptibil-
ity loci for diseases, it is essential that accurate association
analysis can also be performed on the triallelic SNPs iden-
tiﬁed. We ﬁrst investigated whether such an analysis has
higher statistical power than an analysis of biallelic SNPs
that are in LD with these triallelic SNPs, because we ex-
pected some marginal effect on these nearby biallelic
SNPs to be observed as well. To assess the strength of this
marginal effect, we simulated null-allele associations for
600 triallelic SNPs under three association scenarios (asso-
ciation p ¼ 104, p ¼ 106, and p ¼ 108, see Material and
Methods). For each scenario, case and control labels for
each triallelic SNP were assigned in such a way that the as-
sociation p value for the null allele of this SNP approxi-
mated the p value of the scenario under investigation.
Then the association strength of the SNPs used for imputa-
tion purposes could be determined (Figure 2A). The me-
dian marginal effect was 3 3 103, 3 3 104, and 2 3 105
for the three scenarios, respectively, indicating that mar-
ginal effects on the SNPs used for imputation are usually
present but much weaker than for the imputed triallelic
SNP. It can thus be concluded that the statistical power
to detect associations for the null alleles of these triallelic
SNPs is considerably higher than an analysis of the biallelic
SNPs that are in LD with them.
We performed a celiac disease association analysis on the
triallelic SNPs identiﬁed in the data set28 that comprised
1417 UK controls and 768 celiac disease cases. Celiac dis-
ease is a common (1%prevalence), inﬂammatory condition
of the small intestine induced by intake of gluten in wheat,
rye, and barley. Most of the heritability is explained by the
human leukocyte antigen (HLA) component,43 because the
majority of individuals with celiac disease possess HLA-
DQ2 (and the remainder mostly have HLA-DQ8).442008
Figure 2. Association Analysis with Triallelic SNPs and Marginal Effect on SNPs, Used for Imputation
(A) Marginal association signals of SNPs, used for imputing triallelic SNPs, with disease. Fixed associations for the null allele of 600 tri-
allelic SNPs were defined in such a way that each of the triallelic SNPs approximated a Fisher’s exact test p value of 104, 106, or 108.
We then assessed whether a marginal association signal was present within the SNPs that had been used to impute the triallelic geno-
types. The median marginal effect and the cumulative distribution of the marginal association p value for each of these SNPs are shown,
ranked on significance (see text for details).
(B) Quantile-quantile plot of observed versus expected p values in a triallelic SNP null-allele association analysis in celiac disease, for
which cases and controls had been typed on different platforms. Eight triallelic SNPs with a Fisher’s exact test p value < 0.01 are indi-
cated. The linflation factor is 0.96, suggesting no inflation of the test statistic. Three SNPs map within the major histocompatibility
complex region (indicated in red).Recently, we identiﬁed additional susceptibility loci in
a GWA study,28,45,46 in which we performed an association
analysis on 585 fully imputable triallelic SNPs (see Material
andMethods). The results (Figure 2B) indicate that an asso-
ciation analysis on these triallelic SNPs does not lead to in-
ﬂated test statistics, because linﬂation¼ 0.96when calculated
on the lower 90% of the distribution (linﬂation¼ 1.08 when
calculated with all test statistics). This suggests that our im-
putationmethodologyprevents spurious associations; such
a ﬁnding is quite encouraging because the cases and con-
trols had been typed on different arrays (Illumina Human
Hap300 versus Illumina Human Hap550). Eight triallelic
SNPs showed a Fisher’s exact test p value below 0.01 (Table
1). When we expanded the control cohort by adding 445
Dutch controls, all eight SNPs retained a p value < 0.01.
Three of these (rs743862, rs6925912, and rs2517713,
marked red in Figure 2B) map within or very close to the
major histocompatibility complex (MHC) that is highly
polymorphic, has extended LD, and contains the strongly
associated HLA-DQA1 (MIM 146880) and HLA-DQB1
(MIM604305) genes. As such, these null alleles probably re-
ﬂect nearby polymorphisms (located on a celiac-disease-as-
sociatedhaplotype) that affect the annealing of the triallelic
SNP primers. On the basis of dbSNP (build 127), this is
known to be the case for rs743862 (rs28366194 at þ1bp)
and rs2517713 (rs9260378 at þ3 bp). Although such a
secondary ‘‘primer polymorphism’’ is not known for
rs6925912, this cannot be excluded as the MHC is highly
polymorphic. For the remaining ﬁve triallelic SNPs, there
is little evidence for their potential involvement in celiacThe Amdisease, with the notable exception of rs170037. This SNP
maps within a known susceptibility locus (CELIAC2 [MIM
609754] on 5q31-33) that has been identiﬁed in indepen-
dent linkage studies47–49 and was signiﬁcantly linked in
a meta-analysis of four populations.50 It maps in an intron
of the colony stimulating factor 1 receptor (CSF1R [MIM
164770]) that is involved in monocyte to macrophage dif-
ferentiation and innate immunity.51 For CSF1R, some
weak association has also been reported with Crohn’s dis-
ease,52 another inﬂammatory gastrointestinal disorder for
which molecular mechanisms, comparable to celiac dis-
ease, have been implicated.46
It is relevant to note that if the null allele itself is not as-
sociated with disease, but the A or B alleles are, biallelic as-
sumptions will result in either an overestimation or under-
estimation of the effect, depending onwhether the effect is
dominant or recessive, respectively (see details and Fig-
ure 3). Although these triallelic SNPs are usually excluded
from biallelic association analyses, because of observed
HWE deviations, it is possible these deviations remain un-
der the threshold used (usually in GWA studies an exact
HWE p value < 0.0001 is used to exclude SNPs from subse-
quent association analysis28). This is likely to be the case if
the sample size is small, indicating that when associations
are observed for any identiﬁed triallelic SNP under biallelic
assumptions, one should proceed with caution.
Identity of Null Alleles
The detected null alleles within the 1880 triallelic SNPs can
originate from different sources. These SNPs might maperican Journal of Human Genetics 82, 1316–1333, June 2008 1321






















Allele Frequency p Value of SNPs
Used for Imputation on UK
Samples (1 df c2 test)
rs743862a 6 32,489,917 (BTNL2,
HLA-DRA)
12.5% 8.4% 6.3% 2.02 3 105 rs9501626,
rs3817963
0.0132.63 3 1010
rs10050856a 5 23,407,397 (PRDM9) 13.5% 9.6% 10.8% 1.40 3 104 rs10038792,
rs3924616
0.2740.0978
rs10738290b 9 12,730,906 (TYRP1, C9orf150) 3.5% 5.8% 5.8% 5.86 3 104 rs970946,
rs391858
0.8630.002
rs6925912 6 26,084,906 TRIM38 12.0% 15.8% 15.8% 6.10 3 104 rs199750,
rs199741
9.09 3 106 1.70 3 104
rs170037 5 149,420,837 CSF1R 4.9% 7.5% 6.1% 8.58 3 104 rs216148 0.028
rs9389124 6 134,355,478 TBPL1,SLC2A12 4.4% 6.5% 6.0% 0.0034 rs6902440 0.017
rs2517713a,b 6 30,026,078 HLA-A 2.7% 4.4% 5.8% 0.0061 rs2860580,
rs2256902
1.11 3 1016 0.005
rs1468190 16 13,265,389 (ERCC4) 17.3% 20.7% 21.0% 0.0074 rs10492781 0.004
SNPs mapping within major histocompatibility complex (MHC) is indicated in italics; p < 0.01.
a Known polymorphism present within the primer of SNP (dbSNP, build 127).
b Known deletion locus (Database of Genomic Variants, March 2007 release).within deletion CNVs, and such a mapping will result in
the observed triallelic intensity characteristics, but the
null allele might also reﬂect an unknown, third nucleotide
at the physical position of the SNP (e.g., an A/C SNP in fact
Figure 3. Consequences of Mistyping a Null Allele for Case-
Control Association Studies
It is assumed allele A is the true risk allele for various values of g
(relative risk of AA homozygote) and frequencies of the null allele
(p0). The overestimation of the effect under a dominant model
(top figure) and the underestimation of the effect under a recessive
model (bottom figure) are shown.1322 The American Journal of Human Genetics 82, 1316–1333, Juneis an A/C/G SNP). Another explanation could be that,
within the immediately adjacent locus that is complemen-
tary to the 50 bp primer of the SNP, a secondary polymor-
phism is present that affects the hybridization efﬁcacy of
the primer and consequently results in the same triallelic
pattern.31 To gain insight into these classes, we deﬁned
nonoverlapping loci (see Figure 4 and Table 2) by concate-
nating immediately adjacent triallelic SNPs. A total of 208
of the SNPs that were immediately adjacent to the triallelic
SNPs, but which had not been deemed triallelic, were also
added because they showed aberrant intensity characteris-
tics and loss of heterozygosity (see Material and Methods).
This resulted in the identiﬁcation of 1655 different loci in
total.
A total of 145 loci spanned multiple adjacent SNPs,
which suggests these loci reﬂect deletions and this is sup-
ported by an analysis of the Database of Genomic Variants.
Seventy-seven (53%) were already known to be deletions
in this database, and this is much more than expected
(Extreme Value Distribution p value < 1050).
For the remaining 1510 loci that contained only one
SNP, the origin of the extra allele was less obvious: One ex-
planation could be that polymorphisms map within the
locus that is complementary to the 50 bp primer of the
SNP, affecting the hybridization efﬁcacy of the primer
and resulting in this triallelic pattern. These primer poly-
morphisms were observed in 437 (29%) of these loci (Table
2), a ﬁnding that is considerably higher than expected be-
cause secondary polymorphisms are known within the
primer region for 85,045 (16%) of the 550,123 Human
Hap550 SNPs with known mapping (Fisher’s exact test
p value < 1018). Interestingly, when assessing how far
these primer polymorphisms map away from the triallelic
SNP, the two distributions showed a markedly different
distribution (see Figure 5). Primer polymorphisms were2008
Figure 4. Overview of 1655 Triallelic Loci Identified on Autosomes and Chromosome X
Immediately to the left of each chromosome are depicted all the SNPs present on the Illumina Human Hap550 platform. CNVs known in the
Database of Genomic Variants are shown to the right of each chromosome. Next to this, the triallelic loci are shown for which the length of
each bar denotes the null-allele frequency. Blue indicates a single triallelic SNP locus, orange indicates a locus in which multiple adjacent
triallelic SNPs have been identified, and gray indicates a single triallelic SNP locus for which polymorphisms are known within the region
complementary to the primer of the triallelic SNP (dbSNP build 127).usually much closer to the investigated triallelic SNP
compared to the distribution of the other SNPs with
known primer polymorphisms (Wilcoxon Mann-Whitney
p value< 1076). This implies that primers on the IlluminaThe Amplatform usually tolerate polymorphisms well, as long as
these do notmap too close (>10 bp) to the SNP to be typed.
For the 1073 loci without known primer polymor-
phisms, we observed a strong enrichment of deletions,Table 2. Overview of the Genomic Properties of Identified Triallelic SNPserican Journal of Human Genetics 82, 1316–1333, June 2008 1323
known in the Database of Genomic Variants, in light of the
fact that 136 (13%) had been reported in this database (Ex-
treme Value Distribution p value< 1050). Earlier estimates
show that 50%31–60%5 of these loci reﬂect deletions. This
suggests we have detected at least 682 small-deletion CNV
regions (assuming 50% of the 1073 loci reﬂect deletions
and adding the 145 multiple SNP loci). With an observed
median null-allele frequency of 7.6% for these loci, this
suggests we have identiﬁed 99 deletions per individual
on average. An exponential distribution ﬁts the observed
triallelic-locus-size distribution (Figure 6A, median size ¼
7290 bp), supporting previous observations that small
CNVs strongly outnumber larger ones.4,53 A negative bino-
mial distribution ﬁts the observed allele frequency distri-
bution (Figure 6B) well.
Resequencing
We resequenced 23 triallelic SNPs to assess the predicted
proportion of deletions among the identiﬁed triallelic
SNPs (Table 3). For two triallelic SNPs (rs13213842 and
rs7678151), we conﬁrmed that the observed null allele
was indeed due to a primer polymorphism. For the other
21 triallelic SNPs, we observed that the null allele reﬂects
a primer polymorphism in ten SNPs. Small deletions
Figure 5. Distribution of Distance of Secondary Polymor-
phisms Present within Primers of Human Hap550 SNPs
Distribution plot of the distance of secondary polymorphisms pres-
ent within primers of Human Hap550 SNPs to the actual SNP. Poly-
morphisms are known in dbSNP (build 127) for 85,045 of the SNPs
present on the Illumina Hap550 platform within the 50 bp long
primers. For the 1880 fitted triallelic SNPs, this is the case for
437 of the SNPs (expected 235, Fisher’s exact p value < 1018).
When investigating how far away these secondary polymorphisms
are from the actual SNPs, it turns out that within the triallelic
SNPs, these secondary polymorphisms usually map much closer
to the actual SNP than for the nontriallelic SNPs (Wilcoxon-
Mann-Whitney p value < 1076).1324 The American Journal of Human Genetics 82, 1316–1333, Junwere identiﬁed in two SNPs (rs7822381 and rs2486674).
For the other nine triallelic SNPs, no primer polymorphism
was identiﬁed. Additionally, for the samples for which we
had predicted a homozygote deletion, no product was ob-
served, suggesting these reﬂect deletions that are bigger
than the loci we had ampliﬁed. These results support our es-
timate that ~50% of the triallelic SNPs represent deletions.
We also assessed how well the predicted genotypes corre-
spond to the resequenced genotypes. Seventeen SNPs
showed perfect concordance, whereas for six SNPs, this was
not the case. However, for each of these SNPs, the predicted
quality of genotype inference (based on the concordance
between the preliminary triallelic genotypes and imputed
genotypes) was lower than 0.90, suggesting that genotypes
are usually correctly inferred for 1052 (56%) of the 1,880 tri-
allelic SNPs, because these have a concordance value over
0.90 (Table 3, indicated by the black horizontal bar).
Genomic Properties
To gain insight into the enrichment or depletion of certain
genomic features within these loci, we analyzed the three
triallelic-locus categories separately (Table 2, if enrich-
ments and depletions p value was below 0.05, these are in-
dicated). Fewer multiple-SNP loci than expected contained
genes (empiric p value ¼ 0.013), but when the loci con-
tained genes, the number of genes was higher than ex-
pected (empiric p value ¼ 0.035). No depletion or enrich-
ment for these measures was observed in the two other
classes of loci. It has been demonstrated that genes within
CNVs have more paralogs than expected.54 We also ob-
served this for the multiple SNP loci (empiric p ¼ 0.006),
but not for the other two loci classes. Because genes within
known deletions tend to be buffered by paralogs that usu-
ally have quite similar functions, it is likely that genes
within these CNVs are biologically less important. To as-
sess this in a different way, we investigated the number
of known interactions these genes have because various
studies have shown36,55,56 that essential genes tend to
have more interactions than nonessential genes. We as-
sessed this by analyzing a collection of 80,350 known bio-
logical interactions (see Material and Methods) and indeed
observed for the genes within the multiple-SNP loci that
the number of interactions they have is usually signiﬁ-
cantly less than expected (Wilcoxon-Mann-Whitney
p value ¼ 0.004). In addition, various cytogenetic arms
(2q, 3p, 5p, 6p, 8p, and 22q) were enriched for triallelic
loci (empiric p value < 0.05).
Summary statistics for the 1880 triallelic SNPs are pro-
vided as Supplemental Data available online. TriTyper is
freely available for downloading from the author’s website,
along with Java source code. It provides functionality for
discovering triallelic SNPs in data sets in which raw inten-
sity data is available.When only biallelic-genotype calls are
available, TriTyper allows for imputing triallelic genotypes
for 1204 triallelic SNPs of the 1880 SNPs we have identiﬁed
in this study. After assigning triallelic genotypes, TriTyper
can perform association analysis.e 2008
Figure 6. Distribution of Triallelic-Locus Size and Null-Allele Frequency
(A) The triallelic loci for which no polymorphism within the primer is known in dbSNP (build 127) are plotted against the maximum
potential size of each locus, assuming these can reflect deletions (by taking the physical position of the immediately adjacent SNPs
that look normal on the Illumina Human Hap550 platform).
(B) The number of triallelic loci is plotted against the null-allele frequency.Discussion
In this paper, we have described a method (TriTyper) that
uses raw intensity data from the Illumina genotyping plat-
form to identify SNPs with an extra untyped, but common
allele. Ourmethod is the ﬁrst to our knowledge to do this in
case-control data sets byutilizing thepresence of local LD to
improve genotype assignments. Through this approach we
identiﬁed 1880 triallelic SNPs, and for 1204 of these, the LD
patterns permitted inferring the triallelic genotypes with-
out needing access to raw intensity data. This enables asso-
ciation analyses on these SNPs in white European data sets
that have similar LD patterns, but for which only genotype
calls have been made available, or those that have been
generated with completely different platforms.
With the triallelic-genotype calls from TriTyper, highly
robust association analyses can be performed. We have
shown this in a triallelic null-allele association analysis in
celiac disease, for which cases had been run on a different
type of array than that used for the controls, and we saw no
inﬂation of the test statistic. Simulations indicate that our
method has superior power to detect these associations,
compared to an association analysis on the biallelic SNPs
that are in LD and have been used to infer the triallelic
genotypes. The triallelic SNPs identiﬁed also have ramiﬁca-
tions for association analyses that are based on biallelic
assumptions. If, for any of the triallelic SNPs, the null allele
is not associated but the A and B alleles are, the real effect
of the association will be overestimated or underestimated,
depending on a dominant or recessive model, respectively.
The reported associations in celiac disease did not survive
multiple testingwhenweassumedhundredsof thousandsof
biallelic association tests have already been performed in
a GWA analysis. These ﬁndings, however, do provide new
hypotheses for further replication in independent cohorts.
The identity of each of the triallelic SNPs identiﬁed
remains to be established. We observed that 437 triallelicThe AmSNPs showed a triallelic pattern because of a polymorphism
in the region of the primer, usually within 10 bp from the
target SNP (see Figure 5). This artifact should serve as
a warning for all oligonucleotide-based assays, and we
urge researchers to validate putative CNVs with different
techniques. For the remaining 1218 unique loci (in which
immediately adjacent triallelic SNPs had been concate-
nated), we observed a strong enrichment for deletions,
known in the Database of Genomic Variants. We estimate
that, of these loci, 682 reﬂect deletions, suggesting that on
average 99 deletion CNVs per individual were identiﬁed.
This is approximately four times more than what has
been found by other methods using identical oligonucleo-
tide arrays (between 10 and 27 CNVs on average per indi-
vidual1,14,22). The high resolution of our method and the
fact that we take LD into account probably explain this
difference.
Loci that contained multiple SNPs overlapped with
fewer genes than expected, although the total number of
genes for these loci was higher than expected. Comparable
analyses1,54 conﬂict with each other and as such warrants
further clariﬁcation. As shown before,54 genes within these
loci have paralogs more often than expected (p value ¼
0.006). We are the ﬁrst to our knowledge to show that
the genes within these loci also biologically interact with
signiﬁcantly fewer genes than expected (p value ¼ 0.004).
Various avenues for extending TriTyper can be envisaged.
A drawback of our current imputation methodology is that
we assume certain haplotypes have a zero frequency,
which might not reﬂect the reality because of lower LD
than assumed. Therefore, for some of the triallelic SNPs,
it is likely that some of the imputed genotypes will be in-
correct. Consequently, an association analysis using im-
puted triallelic genotypes will have lower statistical power
compared to an ideal situation, in which accurate triallelic
genotypes would be available. We argue this sacriﬁce in
calling accuracy and power because of imputation iserican Journal of Human Genetics 82, 1316–1333, June 2008 1325












rs10504729 - 6 (1 A0, 1 AA, 1 AG, 2 G0, 1 GG) 0.66 Primer polymorphism (C/T, 1 bp) 0
rs2675899a - 10 (2 A0, 2 AA, 2 CA, 2 C0, 2 CC) 0.71 Probably deletion 0
rs13213842 rs35678510,
A/G, þ1 bp
8 (1 A0, 1 AA, 2 AG, 2 G0, 2 GG) 0.71 Primer polymorphism (A/G, þ1 bp) 1 (G0/GG)
rs3131755 - 5 (1 A0, 1 AA, 1 B, 2 BB) 0.75 Primer polymorphism (T/G, þ4 bp) 0
rs195738 - 12 (1 00, 4 A0, 1 AA, 4 G0, 1 GG) 0.79 Probably deletion 2 (A0/AA)
rs8053391a - 4 (2 A0, 1 AA, 1 GG) 0.81 Primer polymorphism (C/G, þ4 bp) 0
rs7678151 rs28542567,
A/G, 3 bp
11 (1 00, 2 A0, 2 AA, 2 AG,
2 G0, 2 GG)
0.83 Primer polymorphism (A/G, 3 bp) 1 (G0/GG)
rs2871198a - 10 (4 A0, 1 AA, 1 AG, 3 G0, 1 GG) 0.86 Probably deletion 0
rs9355606 - 6 (1 A0, 1 AG, 2 G0, 2 GG) 0.86 Probably deletion 0
rs495991 - 4 (2 G0, 2 AG) 0.86 Primer polymorphism (C/G, 1 bp) 1 (G0/GG)
rs10510312 - 6 (3 G0, 1 GG, 2 AG) 0.87 Primer polymorphism (A/C, 1 bp) 1 (G0/GG)




rs11834116 - 4 (1 AA, 1 A0, 1 AG, 1 G0) 0.91 Primer polymorphisms (C/T, 8 bp,
A/G, þ 1bp)
0
rs7083969 - 9 (1 A0, 1 AA, 1 AG, 5 G0, 1 GG) 0.92 Probably deletion 0
rs7083969 - 11 (6 A0, 1 AA, 1 AG, 3 G0, 1 GG) 0.92 Probably deletion 0
rs1109374 - 4 (1 A0, 1 AA, 1 AG, 1 GG) 0.92 Primer polymorphism (C/T, þ3 bp) 0
rs9361448 - 14 (1 00, 5 A0, 1 AA, 1 AC,
5 C0, 1 CC)
0.94 Probably deletion 0
rs11533655a - 15 (2 00, 5 A0, 1 AA, 1 AG,
5 G0, 1 GG)
0.95 Probably deletion 0
rs2254039 - 6 (3 G0, 2 GG, 1 AG) 0.95 Primer polymorphism (C/T, 1 bp) 0
rs2894386a - 17 (2 A0, 8 AA) 0.95 Primer polymorphism (C/T, 4 bp) 0
rs7133541 - 10 (5 A0, 1 AA, 1 AG, 2 G0, 1 GG) 0.96 Probably deletion 0
rs7822381 - 18 (4 A0, 7 AA, 5 AG, 2 G0) 0.97 Deletion (1 bp deletion in primer) 0
rs1551821 - 6 (3 A0, 2 AC, 1 AA) 0.98 Primer polymorphism (A/C, þ1 bp) 0
In total, two known primer polymorphisms, ten previously unknown primer polymorphisms, and 11 probable deletions were found in the observed origin of
null alleles.
a Known deletion locus (Database of Genomic Variants, March 2007 release).acceptable, because it considerably reduces type I errors in
association testing. If different platforms or batches have
been used for genotyping and cases and controls are not
evenly spread28 over these, spurious associations are to
be expected because of the way our calling algorithm ini-
tially discriminates between A0 and AA and between B0
and BB genotypes. If these genotypes can be imputed
with nearby biallelic SNPs, false-positive associations will
be prevented. Although highly sophisticated imputation
algorithms have been described for biallelic SNPs,26,57 it
is not straightforward to use these to resolve this issue.
This is mostly due to the fact that we currently cannot
rely upon phased haplotypes from HapMap, because all
the SNPs within HapMap have been called under biallelic
assumptions. Another complication is the difﬁculty to esti-
mate r2 and to interpret D’ if the number of alleles between
two markers differ.58,59 However, we expect that by incor-
porating some of the concepts underlying these biallelic
imputation methodologies, the accuracy of the imputed
triallelic genotypes can be improved.
Currently, TriTyper can only detect SNPs with a common
extra but untyped allele. We envisage that adaptations to
both our calling algorithm and LD-based genotype imputa-
tion methodology will probably allow identiﬁcation of1326 The American Journal of Human Genetics 82, 1316–1333, Junevery small but common duplications. In addition, studies
that aim to identify rare de novo deletions and duplica-
tions can immediately beneﬁt from our work. Because
the number of samples we have studied is reasonably
high (3102), we were able to identify common triallelic
SNPs that had a null-allele frequency as low as 0.5%. If re-
searchers are not aware of these common triallelic SNPs
and use smaller cohorts, they might deem these SNPs
rare and potentially biologically interesting when aberrant
characteristics are observed in only a few samples. Method-
ologically, the resolution of de novo CNV detection
methods14,22 can also be improved by incorporating LD-
based frameworks: Conceptually, if two SNPs are in very
strong LD, but in one sample a recombination seems to
be present, a de novo duplication or deletion that spans
one of these SNPs could be an alternative explanation.
The Illumina BeadChip arrays we have used here are
strongly biased against CNVs, because SNPs that showed
low call rates, HWE deviations, or many Mendelian
segregation inconsistencies in a subset of the HapMap
samples had been removed during the design of these
chips. This also explains why the observed median null-
allele frequency of the identiﬁed triallelic SNPs was only
7.6%. Because we did not use the most current llumina2008
chips, we expect the newer ones that are better tailored to
target CNVs (e.g., Illumina HumanHap370 and Human-
Hap1M), to lead to greater insight into CNVs.
The Human Gene Mutation Database60 reports 73,411
variants that mostly have a phenotypic effect, of which
~16% are microdeletions and 7% are microinsertions
(smaller than 20 bp), whereas larger deletions and inser-
tions constitute 6% and 1% of the variants, respectively.
This clearly indicates the importance of structural variants
and deletions in both rare and common diseases.6–8 New
statistical CNV detection methods (such as TriTyper) and
more extensive oligonucleotide arrays will undoubtedly re-
sult in the identiﬁcation of many more variants, of which
quite a few will turn out to be associated with disease.
Appendix A. Genotype Calling
Conventional Biallelic-Genotype Calling
When the minor allele frequency (MAF) is sufﬁciently
high, assigning genotypes to biallelic SNPs is usually fairly
straightforward: Three separate clusters will appear (reﬂect-
ing the AA, AB, and BB genotypes) that can usually be
well separated with a clustering algorithm we recently
described.28 This algorithm uses per-sample polar angle q
[q ¼ 2/p * arctan (intensityb/intensitya)] to identify three
clusters of sample for which the standard deviations of
the q values for each cluster are low. This is achieved by ex-
ploring a 2D search space (in which one parameter discrim-
inates between AA and AB samples and the other discrim-
inates between AB and BB samples). The method then
settles upon a certain clustering for which the three cal-
culated standard deviations have a sum that has been
minimized.
Preliminary Triallelic-Genotype Calling
When a SNP is triallelic, but the SNP has been called under
biallelic assumptions for sufﬁcient samples, it is likely that
HWE deviations will be observed. Assuming HWE for the
true alleles A, B, and 0, we can compute the expected fre-
quencies of observed genotypes AA, AB, and BB. From
these we can compute the observed allele frequencies for
A and B. Now the deviation from the HardyWeinberg equi-
librium in those observed genotypes AA, AB, and BB rela-
tive to the genotype frequencies expected from the ob-
served allele frequencies A and B can be computed. It
turns out that the resulting c2 depends on the true fre-
quency of the 0 allele, and of course on the sample size,
but not on the frequencies of the A and B alleles:
c2 ¼ n$p0 2$

4 8p0 þ 5p0 2

,
where n is sample size and p0 the frequency of the 0 allele.
Calculations show that if 3000 samples are typed, a null
allelewith a frequency of 2%orhigherwill on average cause
a HWE deviation that can be demonstrated at the level of
p ¼ 0.05. Figure 7 illustrates how the HWE test statistic de-
pends on the sample size and the frequency of the 0 allele.The AmAlthough these HWE deviations can also arise because of
failed assays, they are explained by an unlabelled allele
in a substantial number of cases.31 We followed up SNPs
when, under biallelic assumptions, the exact HWE p value
was below 0.05 or when the call rate was below 98%. For
these SNPs, we determined whether triallelic genotypes
could be called by introducing two additional parameters
(a and b) to our calling algorithm.
In the initial triallelic genotype-calling procedure, geno-
types 00 are assigned to samples that have a Euclidian
intensity below a. For the remaining samples, we use the
aforementioned calling algorithm to identify three clusters
of samples that are either A0 or AA (A0/AA), are AB, or
either are B0 or BB (B0/BB) (Figure 1B).
Subsequently we partition both the A0 and AA samples
and the B0 and BB samples using parameter b. Nonpseu-
doautosomal chromosome X SNPs provide detailed insight
into the intensity characteristics of these A0, B0, AA, andBB
samples. For these SNPs, females will usually have two cop-
ies, whereas males will only have one copy (Figure 8A). We
investigated 11,652 nonpseudoautosomal chromosome X
SNPs, present on the Illumina Human Hap550 platform,
for which 1417 unrelatedUK samples from the 1958 British
birth cohort had been typed.28 For each of these SNPs, we
linearly scaled the probe intensities, such that the center
Figure 7. HWE Test Statistics, when Analyzing Triallelic SNPs,
Called under Biallelic Assumptions
These calculations show the HWE test statistic for various sample
sizes and different frequencies of the 0 allele. If we incorrectly
assume triallelic SNPs are biallelic, analysis of sample sizes that
are representative of current genome-wide association studies
will result in significant HWE deviations, even when the 0 allele
has a fairly low frequency, e.g., when testing 3000 samples, and
assuming a call rate of 100% for samples having one or two
copies of the A or B allele, triallelic SNPs with a null-allele fre-
quency above 2% have an expected deviation from HWE with
p < 0.05.erican Journal of Human Genetics 82, 1316–1333, June 2008 1327
of the AB cluster was at coordinate (1, 1). We then moved
the origin of theCartesian coordinate system to this coordi-
nate and converted to a polar coordinate system, allowing
Figure 8. Distribution of A and B Allele Intensities of 11,652
Chromosome X SNPs, Present on the Illumina Human Hap-
Map550 Platform
Each dot represents the median coordinate of the A0 (males,
green), AA (females, blue), B0 (males, yellow), BB (females,
red), or AB (females, gray) cluster for a single SNP. The A and B
intensities have been scaled in such a way that for each SNP, the
median AB cluster center is identical for all chromosome X SNPs.
As shown in (A), it is evident that single-copy genotypes (A0
and B0) clearly show different intensity characteristics than AA
and BB genotypes. Another observation is that the A and B probes
have slightly different characteristics, because the A0 and AA
distributions overlap slightly less than the B0 and BB distributions,
indicating that on average, A0 and AA samples can be better
distinguished from each other. To correct for these differences in
intensity characteristics, parameter b is calibrated on these chro-
mosome X SNP distributions. As shown in (B), the genotype-calling
algorithm uses parameter b to distinguish between A0 and AA and
between B0 and BB. For a given b, an angle for the A0 distribution
is determined where the A0 distribution percentile equals b. The
same holds for the angle of the B0 distribution. In the present
example, increasing b increases the angle of the A line slightly
more than it increases the angle of the B line. Examples are shown
where b is 25 ([B], left) and where b is 75 ([B], right), resulting
in different genotype assignments (A0, AA, B0, and BB genotypes
assignments are indicated in yellow, red, green, and blue, respec-
tively).1328 The American Journal of Human Genetics 82, 1316–1333, Juneus to determine a 1D angle distribution for the A0, the
AA, and the B0 and BB samples. These distributions allow
us to introduce parameter b (range [0, 100]), which denotes
both the percentile of the A0 and the percentile of the B0
distributions.We use this parameter to distinguish between
one and two copies (Figure 1C) because the corresponding
percentile corresponds to two different Cartesian rays that
both start from the AB cluster center but have different
angles, for which one ray (reﬂecting the percentile within
the chromosome X A0 distribution) allows us to divide
the A0/AA samples in A0 and AA samples and another ray
(reﬂecting the percentile within the chromosome X B0 dis-
tribution) allows us to divide the B0/BB samples in B0 and
BB samples (Figure 8B). For example, when b ¼ 25 (Fig-
ure 8B, left), for the samples which are either AA or A0,
the samples having an angle to the AB cluster location be-
low 260 will be designated A0 and having an angle above
260 will be designated AA. For samples that are either BB
or B0, those having an angle to the AB cluster location be-
low 192 will be designated BB and those having an angle
above 192 will be designated B0. When b ¼ 75 (Figure 8B,
right), the thresholds for these angles are 271 and 184,
respectively.
It is evident that different a and b values will result in
different triallelic-genotype assignments. To optimize
these, we use an MLE procedure that assumes HWE under
a triallelic model, through the following log likelihood
formula:29
logðlikelihoodÞ ¼ log½ðnaa þ nbb þ nab þ na0 þ nb0 þ n00Þ!
 ½logðnaa!Þþlogðnbb!Þþlogðnab!Þþ logðna0!Þ




þ nab  log

2  pa  pb




þ nb0  log

2  pb  p0





where naa, nbb, nab, na0, nb0, and n00 are the number of in-
dividuals with assigned genotype AA, BB, AB, A0, B0, and
00, respectively, and pa, pb, and p0 are the allele frequencies
of allele A, B, and 0, respectively.
Through analysis of the entire search space, the values
for a and b for which this likelihood is maximal can be de-
termined (Figure 1D), indicating that the assigned geno-
type distribution most closely resembles the distribution
expected under triallelic HWE. Identiﬁed triallelic SNPs
are included for follow-up analysis, if the null-allele fre-
quency is over 0.5% and the ﬁtted b parameter value is
between 6 and 97.
Eventual Triallelic-Genotype Calling
through Imputation
To improve upon the initially assigned triallelic genotypes,
we take advantage of local linkage disequilibrium, because
the presence of LD between biallelic SNPs can often be uti-
lized to improve genotype assignments.26,27,57 Because LD
has been described for deletion CNVs as well,1,2,24,25,61 we2008
Figure 9. Imputation Scenarios
When assuming all alleles have a nonzero frequency for both the triallelic SNP and the neighboring biallelic SNP and that some LD is
present (i.e., at least one haplotype has not been observed), there are 24 different imputation scenarios possible. For ten of theseThe American Journal of Human Genetics 82, 1316–1333, June 2008 1329
assumed these triallelic genotypes can potentially also be
inferred through LD.
To assess this, we require that at least one of the six hap-
lotypes should have a zero frequency and that all alleles are
present for the biallelic SNP and triallelic SNP, resulting in
the identiﬁcation of 24 ‘‘haplotype scenarios’’ that each
have a different set of haplotypes that have not been ob-
served (Figure 9). For each of these scenarios, a set of trial-
lelic-genotype imputation rules can be easily deduced. It
turns out that ten scenarios are capable of discriminating
between A0 and AA and/or between B0 and BB triallelic ge-
notypes. This is very helpful because in the initial geno-
type-assignment procedure, a somewhat rough division is
made between the A0 and AA genotypes and between
the B0 and BB genotypes (through optimization of param-
eter b). As such, it is likely that some incorrect genotypes
(Figure 1E) have initially been assigned to samples that
cluster in the vicinity of the two dividing rays determined
by parameter b (e.g., the initially assigned A0 genotype
should actually be AA and vice versa). This is resolved if
nearby biallelic SNPs allow for discrimination between
A0 and AA and between B0 and BB samples. We concen-
trate on any of these ten scenarios throughout this paper
and will assess these for each triallelic SNP.
We ﬁrst assess the LD for each triallelic SNP identiﬁed
with the immediately adjacent biallelic SNPs (10 to the
left and 10 to the right): For each pair, haplotype frequen-
cies (haa, hab, hba, hbb, h0a, and h0b) are estimated with an
expectation-maximization algorithm.62 If the frequencies
of some of these haplotypes are zero (e.g., haplotypes
haa, hba, and h0b have a zero frequency, as in Figure 1F),
it is determined whether this conﬁguration of observed
and nonobserved haplotypes matches one of the ten hap-
lotype scenarios for which the biallelic SNP helps to dis-
criminate between some of the triallelic genotypes, and
we use the neighboring SNP for imputation. Because of
the uncertainties mentioned for the initially assigned trial-
lelic genotypes, certain estimated haplotypes frequencies
will be incorrect, resulting in haplotypes with nonzero fre-
quencies that in reality should have a zero frequency (Fig-
ure 1F). In order to overcome this, we relaxed our method
for assessing the imputation potential of each neighboring
biallelic SNP: We assumed that haplotypes with low, but
nonzero frequencies in reality might have a zero fre-
quency. For each haplotype, it was determined whether
the frequency was lower than the frequency of the haplo-
type with the same triallelic allele, but with a different bial-
lelic allele. If this was the case, we assumed that this haplo-
type in reality might have a zero frequency. To ascertain
this, we tested all possible haplotype scenarios (through
systematic inclusion and exclusion of these potentially
zero-frequency haplotypes) and assessed whether any of1330 The American Journal of Human Genetics 82, 1316–1333, Junethese scenarios could help to discriminate between A0
and AA or between B0 and BB. If this was observed, we
searched for evidence that our zero-frequency assumption
for these haplotypes was indeed correct, by imputing the
A0 and AA or B0 and BB genotypes and testing whether
the Euclidian intensities of the imputed A0 or B0 samples
were signiﬁcantly lower (Wilcoxon-Mann-Whitney test
p < 103) than the Euclidian intensities of the AA or BB
samples. In addition, we tested whether the concordance
between the imputed and observed genotypes was higher
than 60%. If this was observed, we assumed this haplotype
scenario could be used for imputation purposes and stored
it in a vector. Once all haplotype scenarios had been
assessed for each of the 20 biallelic neighboring SNPs, we
selected the imputation scenario that had the highest ge-
notypic concordance and that could help to discriminate
between A0 and AA and the imputation scenario with
the highest genotypic concordance that could help to dis-
criminate between B0 and BB. This sometimes resulted in
the identiﬁcation of one single biallelic SNP, in perfect LD
with the untyped allele of the triallelic SNP that could be
used to discriminate both between A0 and AA and between
B0 and BB genotypes.
Appendix B. Consequences of Miscalling Null
Alleles in Case-Control Studies
If the presence of a null allele is not recognized, this will
have consequences for case-control association studies.
The easiest case is when the null allele is itself the risk al-
lele. If it is not recognized as such, the SNP will give no sig-
nal at all when assuming the A0 and B0 genotypes confer
the same risk. However, it is likely that these SNPs will
be removed from the analysis because HWE deviations
are expected to appear and lower call rates will become
apparent.
It is more complicated for cases in which allele A is the
risk allele. Taking the above scenario, we can calculate
the odds ratio (OR) of allele A versus nonallele A for the sit-
uations in which the null allele is recognized and not rec-
ognized. For simplicity, we will limit ourselves to a domi-
nant and a recessive model. In the dominant model, for
the observed OR (allele A versus nonallele A) in which
the null allele is not recognized, we get:
ORAðobsÞ ¼
g
ða 1ÞpB þ 2p0
þ ðag 1ÞpA

ðag 1Þ2p0 þ gpA þ pB
 :
Also, if the null allele is typed correctly:
ORAðrealÞ ¼
g
ða 1ÞpB þ p0
þ ðag 1ÞpA

ðag 1Þp0 þ gpA þ pB
 ,scenarios, the biallelic SNP can help to discriminate between B0 and BB and/or between A0 and AA for the triallelic SNP. For the first
imputation scenario, a detailed description of this procedure is provided: With this set of observed and unobserved haplotypes, a limited
number of genotype combinations exist. This allows for deducing a set of genotypic rules that can help to discriminate between B0 and BB
genotypes for the triallelic SNP, on the basis of the genotype of the neighboring biallelic SNP.2008
where pA, pB, p0 are the allele frequencies of the respective
alleles, a is the disease risk for genotypes not containing
A, and ag is the disease risk for individuals carrying one
or two A alleles. Note the difference of 2p0 and p0 in both
denominator and numerator between the two equations.
For the recessive model, in which penetrance for AA
homozygotes is still ag and penetrance for all other geno-
types is a:
ORAðobsÞ ¼
ða 1ÞpB þ 2p0 þ gpA

ða 1Þ2p0 þ pB
þ ðag 1ÞpA
:
Also, if the null-allele is typed correctly:
ORAðrealÞ ¼
ða 1ÞpB þ p0 þ gpA

ða 1Þp0 þ pB
þ ðag 1ÞpA
:
Figure 3 depicts the consequences of mistyping on the
observed OR: OR is overestimated for the dominant model
and underestimated for the recessive model. The amount
of overestimation or underestimation depends on the rela-
tive penetrance (g) of the risk allele and the null-allele
frequency.
Supplemental Data
One spreadsheet is available at http://www.ajhg.org/.
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